Menu
image description

Tag: ustekinumab

LRA Applauds Exciting Lupus Research Being Presented at 2019 ACR/ARP Annual Meeting

Includes 16 presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from two clinical studies conducted by LRA-affiliate Lupus Therapeutics (LT) in collaboration with Rilite Foundation and Pfizer to be presented Extensive positive studies focused on lupus, including successful Phase 3 and Phase 2 clinical and mechanistic data […] Read More

Study Shows Need for Greater Awareness of Biologics for Lupus

August 19, 2019 A new study led by Dr. S. Sam Lim of Emory University found a need for more awareness of biologic therapies among both black and white people with lupus.  Biologics are medicines that come from living cells to prevent, treat and cure human diseases, and are designed to have specific effects on […] Read More

Stelara® Effective Over One Year and Reduces Severe Flares

Results of two analyses from a Phase 2 study of Stelara® (ustekinumab) in lupus showed the drug’s effectiveness over one year. Both highlight the benefit of ustekinumab on disease activity and the rate of severe flares. Ustekinumab reduced the rate of severe flares four times as much as placebo by week 24. The rate of […] Read More

Updates in Lupus Clinical Research from the LUPUS 2019 Meeting

April 11, 2019 The Lupus Research Alliance is pleased to share the results from four clinical trials presented at LUPUS 2019.  These studies continue to push our way forward toward new and improved treatments to help the lupus community. There’s a Silver Lining in New Belimumab Results Jim Oates, MD, Medical University of South Carolina, […] Read More

ACR|ARHP News on Potential New Lupus Treatments

October 25, 2018 The Lupus Research Alliance was on the ground at the American College of Rheumatology 2018 meeting to bring you the latest news in lupus research and translation.  Several clinical trials showed benefits of potential new treatments for helping people with lupus. Following are summaries of the stand-out results: Ustekinumab (Stelara®) A Phase 2 […] Read More

Lupus Research Alliance and Lupus Therapeutics Partner on New Phase 3 Trial Testing Potential Benefit of Ustekinumab (Stelara®) in Lupus

February 1, 2019 The Lupus Research Alliance announced that its affiliate Lupus Therapeutics is working with the pharmaceutical company, Janssen, to help conduct a Phase 3 trial to evaluate whether their drug ustekinumab (Stelara®) may offer benefit to people with lupus.  Called LOTUS, the international study is being conducted in over 200 sites, 20 of […] Read More

Stelara® and Olumiant® Considered Promising by Lupus Expert

February 19, 2019 In Healio Rheumatology, Dr. Gregg Silverman, professor of medicine and pathology at NYU School of Medicine, provided an overview of potential lupus therapies in development.  He highlighted ustekinumab (brand name Stelara®) and baricitinib (brand name Olumiant®) as two drugs that look particularly promising. “The phase 2 extra-renal trial of baricitinib looks good; […] Read More